source
- Attovia, Braveheart Bio, and Vogenx aim to raise over $500M through combined IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have each filed IPO paperwork, setting price ranges that together target more than $500 million in gross proceeds from public investors. Braveheart…
- EFPIA urges EU lawmakers to further cut clinical trial approval timelines under Biotech ActThe European Federation of Pharmaceutical Industries and Associations (EFPIA) has asked EU legislators to go beyond the modest reductions in clinical trial approval times that are currently being c…